首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4245篇
  免费   268篇
  国内免费   52篇
耳鼻咽喉   21篇
儿科学   76篇
妇产科学   95篇
基础医学   248篇
口腔科学   61篇
临床医学   728篇
内科学   477篇
皮肤病学   54篇
神经病学   344篇
特种医学   310篇
外科学   1093篇
综合类   460篇
预防医学   186篇
眼科学   14篇
药学   222篇
  3篇
中国医学   51篇
肿瘤学   122篇
  2024年   7篇
  2023年   72篇
  2022年   200篇
  2021年   180篇
  2020年   180篇
  2019年   156篇
  2018年   166篇
  2017年   125篇
  2016年   147篇
  2015年   153篇
  2014年   338篇
  2013年   292篇
  2012年   262篇
  2011年   283篇
  2010年   271篇
  2009年   226篇
  2008年   228篇
  2007年   204篇
  2006年   161篇
  2005年   148篇
  2004年   98篇
  2003年   89篇
  2002年   66篇
  2001年   43篇
  2000年   54篇
  1999年   36篇
  1998年   41篇
  1997年   36篇
  1996年   28篇
  1995年   34篇
  1994年   25篇
  1993年   23篇
  1992年   24篇
  1991年   14篇
  1990年   21篇
  1989年   18篇
  1988年   23篇
  1987年   7篇
  1986年   7篇
  1985年   13篇
  1984年   7篇
  1982年   7篇
  1981年   4篇
  1980年   5篇
  1979年   10篇
  1977年   3篇
  1976年   6篇
  1973年   6篇
  1972年   5篇
  1971年   3篇
排序方式: 共有4565条查询结果,搜索用时 15 毫秒
91.
92.
目的 比较PICC和植入式静脉输液港(implantable venous access port,PORT)从置管到拔管全程的成本-效果,为中长期中心静脉输液技术的选择提供卫生经济学依据。 方法 采用回顾性队列研究,便利地选取上海市某三级甲等医院2016年1月—2019年10月采用PICC进行静脉输液的444例患者及2013年1月—2019年10月采用PORT的477例患者为研究对象,采用成本-效果分析,从医院角度比较两组总留置时间段、留置3~6个月、6~9个月、9~12个月时的总成本、综合效果指数、成本-效果比。 结果 在总留置时间段、留置3~6个月、6~9个月、9~12个月时,PICC组的日均总成本或总成本均低于PORT组,差异具有统计学意义(P<0.001);PICC组综合效果指数均略低于PORT组;PICC组的成本-效果比均低于PORT组;增量成本-效果比分别为543.50、234 411.00、120 092.25和109 164.00。 结论 当导管留置时间≤12个月时,PICC成本-效果优于PORT,从卫生经济学角度,优先推荐PICC作为中长期静脉输液通路。此外,增量成本-效果比可辅助决策,若支付意愿值高于增量成本-效果比,则PICC和PORT均为成本-效果可接受的方案;反之,则PICC成本-效果更佳。  相似文献   
93.
目的:探讨舌静脉畸形(venous malformations,VM)的数字减影血管造影(digital substraction angiography, DSA)分型及治疗策略。方法:总结2016年2月—2019年2月收治的132例舌VM患者的DSA表现,根据影像学特征将其分为4型,Ⅰ型为无回流型、Ⅱ型为低回流型、Ⅲ型为高回流型、Ⅳ型为广泛型,依据分型选择不同的治疗方案。无回流型单纯采用平阳霉素进行硬化治疗,低回流型单纯采用聚桂醇泡沫硬化剂进行硬化治疗,高回流型采用无水乙醇结合聚桂醇泡沫硬化剂进行硬化治疗,广泛型先按高回流型进行硬化治疗后再结合整形手术切除。统计各组病例的治疗效果及不良反应。结果:本组132例病例获得12~41个月随访,平均15.8个月,所有患者术后舌VM明显缩小甚至消失。Ⅰ型8例,有效率100%;Ⅱ型17例,有效率100 %;Ⅲ型98 例,有效率90.8 %;Ⅳ型 9例,有效率77.8%。不良反应主要为组织溃烂、坏死,Ⅰ型0例;Ⅱ型1例,发生率5.88%; Ⅲ型16例,发生率16.33%;Ⅳ型7例,发生率77.78%。结论:基于DSA的舌VM分型对临床治疗具有重要指导意义。舌VM中大部分为Ⅲ型病例,Ⅰ型比例最小。经黏膜注射无水乙醇是治疗高回流型和广泛型舌VM的有效方法。  相似文献   
94.
Coronavirus disease 2019 or most commonly known as COVID-19 is a trending global infectious disease which a few months ago was affirmed as a global health emergency or a pandemic by the WHO Emergency Committee. The common symptoms manifested in this pandemic disease are high grade fever, cough, fatigue, shortness of breath and flu like symptom which can evolve into severe respiratory disorders such as pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Factors that contribute to the severity or high mortality rate in COVID-19 include old age, comorbidities like hypertension, diabetes, hyperlipidaemia, neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and other various coagulopathies including Venous thromboembolism have known to become a major contributing factor to high mortality rate. Venous thromboembolism is a disease which is a combination of deep vein thrombosis and pulmonary embolism. Prophylactic anticoagulation in patients prone to or with a pre-existing history of venous thromboembolism is associated with decreased mortality in severe COVID-19 pneumonia. This review article focuses upon COVID-19 and increased incidence of venous thromboembolism in patients infected by COVID-19 along with the role it has in high mortality rate in COVID-19 patients.  相似文献   
95.
The endovenous revolution has accelerated the development of new techniques and devices for the treatment of varicose veins. The ClariVein® mechanochemical ablation device offers tumescentless treatment with a rotating ablation tip that can theoretically become stuck in tissue. We present the first report of retrograde stripping of the small saphenous vein without anaesthesia following attempted use of the ClariVein® device, without adverse sequelae.  相似文献   
96.
目的 探讨急性下肢深静脉血栓形成患者肺栓塞严重程度的危险因素.方法 本研究为前瞻性研究.2010年7月至2012年7月收集首都医科大学附属北京世纪坛医院血管外科诊断的急性下肢深静脉血栓形成的患者资料,其中符合纳入、排除标准的208例患者纳入本研究.其中男性101例,女性107例,平均年龄(59±16)岁.利用肺动脉CT血管造影、肺动脉磁共振血管造影或肺动脉数字减影血管造影筛查肺栓塞,并评估其肺栓塞程度.采用x2检验和Logistic回归对深静脉血栓形成患者发生肺栓塞程度的危险因素进行单因素和多因素分析.结果 208例下肢深静脉血栓形成患者中70例发生肺栓塞,总体发生率为33.7%.单因素分析结果显示,下肢深静脉血栓范围(x2=17.286,P=0.004)、下肢深静脉血栓部位(x2=15 602,P=0.008)对肺栓塞的严重程度有影响.年龄(x2=7.099,P=0.260)、性别(x2=7.014,P=0.067)、明显血栓危险因素(x2=3.335,P=0.345)对肺栓塞的严重程度无影响.多因素有序Logistic回归分析显示肺栓塞的程度随着下肢深静脉血栓范围的扩大和部位的增加而加重,髂股静脉血栓(OR =6.172,95% CI:1.590 ~ 23.975,P=0.009)、双下肢深静脉血栓(OR=7.140,95% CI:2.406 ~ 24.730,P=0.001)是肺栓塞严重程度的独立危险因素.结论 髂股静脉血栓形成、双侧下肢深静脉血栓形成是发生严重肺栓塞的独立危险因素,对这些高危患者应更加注重肺栓塞的防治.  相似文献   
97.
新鲜下肢骨折术前深静脉血栓形成危险程度评分量表初探   总被引:5,自引:0,他引:5  
目的 初步尝试建立新鲜下肢骨折术前深静脉血栓形成危险程度评分量表,用于院内下肢骨折患者术前深静脉血栓形成危险程度的客观判断.方法 回顾性分析2011年1月至2012年12月北京积水潭医院创伤骨科治疗的新鲜下肢骨折患者资料,依据排除标准剔除病例后共纳入分析1 705例.这些患者被随机分为两组,研究组(879组)通过logistic回归分析筛选出危险因素,以多因素logistic回归OR值赋分的方法产生新鲜下肢骨折术前深静脉血栓形成危险程度评分量表,检验组(826例)对评分表进行验证.结果 纳入患者中男性1 106例,女性599例;平均年龄(50±18)岁,logistic回归分析显示可以预测深静脉血栓形成的因素包括年龄、待术时间、受伤原因、受伤部位、心脑血管疾病史以及D-二聚体(D-Dimer)检测值.根据回归OR值得出的分值分别是:年龄≤35岁为1分,>35 ~ <65岁为4分,≥65岁为6分;待术时间<8d为1分,≥8d为2分;受伤原因低能量为1分,高能量为3分;受伤部位中,足踝损伤为1分,小腿骨折为3分,膝关节周围骨折为5分,股骨中上段为7分,骨盆髋臼为4分,多发骨折为6分;无心脑血管疾病史为1分,有心脑血管疾病史为2分;D-Dimer< 600 μg/L为1分,≥600μg/L为3分.受试者工作特征曲线下面积为0.79,临界点15.5分,总体数据临界点灵敏度为77.00%,特异度为68.17%.结论 新鲜下肢骨折术前血栓危险程度评分量表对深静脉血栓形成具有一定的预测效能,但是存在局限性.  相似文献   
98.

Background

Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency.

Methods

In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors.

Results

After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction <.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer.

Conclusion

A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.  相似文献   
99.
Angiography using prostaglandin E1 was performed on 34 patients with carcinoma of the colon in order to define the degree of venous invasion. Venous findings on angiogram (occlusion and/or encasement) were classified into three groups: AG-V2, above-mentioned venous findings up to marginal vein; AG-V1, these findings up to the vasa recta; AG-V0, no distinct findings on the vein. These venous findings were compared with histologic subserosal venous invasion that was diagnosed with both hematoxylin and eosin and elastica van Gieson's staining. When angiographic findings were compared with histologic subserosal venous invasion, the results of AG-V2, AG-V1, and AG-V0 showed a positive correlation of 92.3 percent, 46.7 percent, and 16.7 percent, respectively. The angiographic findings were also correlated with the degree of fibrosis around the carcinoma of the colon. The incidence rate of liver metastasis in a group of AG-V2 was 46.2 percent. In AG-V1 it was 26.7 percent and in AG-V0 0 percent. In the course of the postoperative follow-up, liver metastases appeared in two cases of AG-V2 and AG-V1, respectively. This finding may suggest the presence of liver micrometastases at the time of surgery.  相似文献   
100.

Purpose

In this study, we aimed to estimate recurrence risk after incident venous thromboembolism, stratified according to unprovoked, provoked, and cancer-related venous thromboembolism in a prospective cohort of inpatients and outpatients receiving routine care.

Methods

We linked nationwide Danish health registries to identify all patients with incident venous thromboembolism from January 2000 through December 2015. Rates of recurrence were calculated and Cox regression was used to compute hazard ratios (HRs) with 95% confidence intervals (CIs) by incident venous thromboembolism type after adjusting for coexisting risk factors.

Results

The study included 73,993 patients with incident venous thromboembolism (54.1% females; mean age, 62.3 years). At 6-month follow-up, rates per 100 person-years were 6.80, 6.92, and 9.06 for provoked, unprovoked, and cancer-related venous thromboembolism, respectively. At 10-year follow-up, corresponding rates were 2.22, 2.84, and 3.70, respectively. Additionally, at 6-month follow-up, hazard rates of recurrence were comparable for patients with unprovoked venous thromboembolism 1.01 (95% CI, 0.92-1.11) and provoked. At 10-year follow-up, unprovoked venous thromboembolism (HR, 1.17; 95% CI, 1.12-1.23) and cancer-related venous thromboembolism (HR, 1.21; 95% CI, 1.12-1.32) were associated with higher risk of recurrence compared with that found in provoked venous thromboembolism.

Conclusions

In this nationwide cohort, patients with cancer-related venous thromboembolism had the highest risk of recurrence. At 6-month follow-up, there were similar risks of recurrence for patients with unprovoked and provoked venous thromboembolism. At 10-year follow-up, recurrence risks were similar for patients with unprovoked venous thromboembolism and patients with cancer-related venous thromboembolism. High recurrence risks in all categories indicate that further research is needed to optimize duration of extended anticoagulation for these patients.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号